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The existing systems of classification of carcinogens should include a distinction between genotoxic and 
non-genotoxic chemicals. For non-genotoxic chemicals, permissible exposure levels can be derived at which 
no relevant human cancer risks are anticipated. While genotoxic carcinogens can induce chromosomal 
effects without mutagenic action, non-DNA-reactive genotoxins affecting topoisomerase or the spindle, 
or those having an exclusively aneugenic effect can be carcinogenic only at high, toxic doses. Specific 
mechanisms of clastogenicity and processes of carcinogenesis based on reactive oxygen have practical 
thresholds. Since reactive oxygen species (ROS) are generally genotoxic, the question is whether chemicals 
that increase ROS production will add to endogenously produced background levels and lead to non-
linear dose-effect relationships. Taking into account the presence of endogenous carcinogens, it is now 
becoming evident that carcinogenic risk extrapolation to low doses must be considered according to the 
mode of action.
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In the EU directives, carcinogens are classified 
according to a system which was introduced in the 
early eighties and which was based on the existing 
national systems. The decision making completely 
separates the sequential processes of "hazard 
assessment", which is directed towards classification, 
from labelling and "risk assessment" which is directed 
towards standard setting. Both the categorisation and 
the procedures for low-dose extrapolation of the risk 
of chemical carcinogens are now being discussed on 
the international level (1). The general idea is that the 
classification of carcinogens should be more based 
on mechanisms which trigger carcinogenic effects 
and should take more account of their potency. 
This proposal of a new classification of carcinogens 
includes additional considerations about germ-cell 
mutagens (2-4).
The German Senate Commission of the 
Deutsche Forschungsgemeinschaft (German Science 
Foundation) for the Investigation of Health Hazards in 
the Work Area (5, 6) has issued new recommendations 
to distinguish between five groups of proven and 
suspected carcinogens instead of three. Category 
1 includes proven human carcinogens according to 
data on exposure, epidemiology and mechanisms 
of action. Category 2 includes suspected human 
carcinogens according to experimental animal data 
supported by data from epidemiological studies. 
Category 3 includes substances which raise concern 
because of their carcinogenic potency in experimental 
models, but which still lack relevant data. The 
proposed new categories are Category 4 "substances 
with carcinogenic potential for which genotoxicity 
plays no or at most a minor role. No significant 
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contribution to human cancer risk is expected, 
provided that the Maximum Allowable Concentration 
(MAK) value is observed" and Category 5 of the 
new MAK system, which includes "substances with 
carcinogenic and genotoxic potential, the potency 
of which is considered so low that, provided that the 
MAK value is observed, no significant contribution to 
human cancer risk is to be expected."
CLASSIFICATION OF CARCINOGENS
For a number of chemical carcinogens (as well 
as for ionising radiation), the assumption of a linear 
dose-response relationship without threshold has 
been plausibly supported and the resulting linear non-
threshold (LNT) extrapolation seems appropriate and 
scientifically well founded. This linear dose-response 
relationship seems adequate for a number of genotoxic 
carcinogens, such as aflatoxin B1, the tobacco-specific 
nitrosoketone N-methyl-nitrosopyridylbutanone NNK, 
and probably N,N-diethylnitrosoamine (7).
Other carcinogens may behave differently, but 
the precise nature of the dose-response at low doses 
has not sufficiently been established. However, 
extrapolation models connecting the high level 
risk to zero intercept have clearly resulted in the 
overestimation of risk, as was the case with vinyl 
acetate (7). It suggests that, in the low-dose range, 
a mechanism may be operative that prevents the 
formation of DNA damage, for instance DNA adducts, 
or translation of DNA adducts to mutations. Other 
relevant effects which promote tumour formation 
are the activation of oncogenes/inactivation of 
tumour suppressor genes as a consequence of DNA 
damage and the formation of preneoplastic lesions 
as a consequence of activated oncogenes (7). In 
principle, in vitro studies have already shown that that 
practical thresholds may apply for specific protective 
mechanisms such as metabolic inactivation. However, 
different tissues may differ in metabolic inactivation 
of the same compound (7-9). 
Improvements in carcinogenicity testing in 
experimental animals and structure-activity correlations 
have provided new insights for the prediction of 
carcinogenic potential (10). There is a growing 
recognition that non-tumour data, such as information 
on metabolism, formation of DNA adducts, various 
other types of DNA damage, pharmacokinetic models, 
and the information on the mode of action can be 
important in elucidating the carcinogenic effect in 
the low concentration range. A review of non-tumour 
data for 1,3-butadiene, vinylchloride and benzene and 
general guidelines for their use are given in detail in 
Albertini et al. (10).
There is more uncertainty with other chemicals 
for which LNT extrapolation may be used as a default 
procedure. Precautionary considerations will in their 
case mostly lead to a conservative approach to linear 
low-dose extrapolation.
There is an almost general agreement that 
genotoxic and non-genotoxic chemicals should be 
distinguished when assessing cancer risk to humans. 
Non-genotoxic carcinogens (hormones, tumour 
promoters, or 2,3,7,8-tetrachlorodibenzo-p-dioxin 
[TCDD]) are characterised by a "conventional" dose-
response, which makes it possible to derive the no-
observed-adverse-effect-level (NOAEL). Including 
an uncertainty (or safety) factor makes it possible to 
derive permissible exposure levels at which no relevant 
human cancer risk is anticipated.
Risk assessment
Carcinogens are basically classified in a two-step 
hazard identification procedure, followed by risk 
characterization where hazard estimates are calculated 
to lifetime hazard after lifelong exposure to a virtual 
dose (Figure 1). The result describes a lifetime cancer 
risk related to daily intake by food, water or air, and 
is presented as cancer cases per 100.000 people. It 
is important to note that these data are related to a 
virtual scenario and that these cases are not to be 
expected in reality.
It is important to know how the tumourigenic 
dose is estimated to characterise the risk. The US 
Environmental Protection Agency (EPA) has proposed 
to use LED10 as the reference point. LED10 is the lower 
95 % confidence limit for the dose which induces 
tumours in 10 % of exposed animals in experimental 
models (11-13).
As a descriptor of carcinogenic potency, Dybing
et al. (12) have introduced the "T25 concept". As a 
recent example, they used this concept to assess the 
risk of acrylamide in food (13). Generally, the T25 
dose is defined as the dose yielding a 25 % cancer 
incidence in an animal experiment (12). Again, 
the T25 method assesses the risk at low exposure, 
assuming proportionality through linear extrapolation 
(T25/linear). The T25/linear and other extrapolation 
methods based on metrics such as LED10 assume 
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linearity which may be invalid. Any risk calculated 
using the T25/linear method would provide a precise 
risk figure similar to the output obtained from the 
linearised multistage  method (LMS) formerly used 
by the US EPA. However, uncertainties such as the 
false assumption of precision and non-linearity in 
the dose-response curve for tumour induction raised 
concerns against the use of T25/linear method for 
predicting human cancer risk (11).
NEW VIEWS ON THE MECHANISM OF 
GENOTOXIC CARCINOGENS
Insights into the mechanisms of a whole array of 
different genotoxic carcinogens have raised questions 
about the strict application of linear non-threshold 
(LNT) extrapolation models.
Compounds with an aneugenic but not mutagenic 
effect may be characterised as carcinogenic only at 
high, toxic doses (14). Effects such as aneuploidy, 
chromosome loss and non-disjunction have received 
particular attention (15-17). There is a wide consensus 
that dose-response thresholds should be defined for 
non-DNA reactive genotoxins such as aneugens (18, 
19).
It is being discussed whether clastogenic 
mechanisms have a dose-effect threshold, as 
discussed for toposisomerase II poisons (20) or 
mechanisms based on reactive oxygen (21, 22). Yet, 
the general inclusion of clastogens is viewed critically 
by a number of authors (23). 
Non-DNA-react i ve  genotox ins ,  such as 
topoisomerase inhibitors (20, 24) or the inhibitors 
of the spindle apparatus and associated motor 
proteins (16, 17, 25, 26), are considered to have 
"practical" thresholds and relevant arguments have 
been put forward in favour of this argument (15, 
27). Colcemid and vinblastine induce aneuploidy by 
modifying the number of spindle fibres which regulate 
the segregation of chromosomes during mitosis and 
meiosis. It is expected that polyploidy or aneuploidy 
are induced only if most fibres are damaged, because 
of their redundancy in dividing cells. This effect helps 
to understand that a threshold was experimentally 
established. 
Genotoxicity, especially when of local nature, 
may only be relevant under conditions of sustained 
local tissue damage and the associated increased 
cell proliferation. Cases in point are formaldehyde 
(28-30) and vinyl acetate (7, 31). Defining practical 
thresholds and health-based exposure limits for these 
two compounds may prove justified.
High doses of reactive oxygen species (ROS) 
or ROS promotors are clearly toxic. ROS are 
involved in many forms of tissue damage such as 
ischemia-reperfusion, atherosclerosis, radiation 
injury, aging and carcinogenesis (22, 32). Generally, 
"oxidative stress" is an important mechanism of 
indirect genotoxicity that is triggered by exposure 
to exogenous factors such as UV, ionising radiation, 
anoxia and hyperoxia. Other pathways are mediated by 
chemicals producing reactive oxygen species (33, 34). 
Paraquat and certain oxidants (potassium bromate, 
hydrogen peroxide) are the classical examples in this 
respect. Other exogenous sources of ROS are tobacco 
smoke, fatty acids, transition metals, ethanol, redox 
cycling compounds or physical irradiation by multiple 
sources. ROS interact with critical molecules within 
cells and with intracellular signalling, leading to cell 
death, mutagenesis and toxicities associated with lipid 
peroxidation. Increased oxidative stress and excessive 
ROS production cause damage to DNA modifying the 
Figure 1  The existing system of classification of genotoxic carcinogens 
through hazard identification and risk assessment
Foth H, et al. NEW ASPECTS IN THE CLASSIFICATION OF CARCINOGENS
Arh Hig Rada Toksikol 2005;56:167-175
170
base and altering DNA strands, and can contribute 
to cancer. This is evident from many studies using 
sensitive methods for the detection for oxidative DNA 
damage (35).
Presently it is difficult to define the precise role 
of ROS-induced DNA damage in carcinogenesis 
and how genetic and epigenetic events induced 
by ROS affect cell transformation and progression 
of malignancies. Effects observed under oxidative 
stress (i.e. increased oxidative DNA damage) are 
inconclusive due to pronounced epigenetic effects of 
ROS on signal transduction and gene expression (36). 
Many aspects have been elucidated so far, indicating 
that at low levels of ROS adaptive responses are active 
on the side of repair and antioxidative defence, and this 
strengthens non-linear dose-response relationships 
between low and high levels of ROS (Figure 2).
In general, the idea that ROS-mediated processes 
of carcinogenesis should have at least practical 
thresholds is receiving more and more support from 
the scientific community (22).
ENDOGENOUS PROCESSES
Antioxidative defense against oxidative stress
High internal doses of ROS or high levels of ROS 
stimuli are clearly genotoxic, and in this context 
the effect of antioxidants is primarily beneficial. 
Regarding the role of antioxidants in cancer prevention 
strategies, numerous epidemiological studies support 
a protective role of dietary antioxidants in cancer 
prevention (35). On the other hand, epidemiological 
studies designed as intervention studies in high-risk 
subjects also indicate a tumour-promoting effect of 
beta-carotene supplements (37). This may be due to 
the fact that dietary antioxidants protect cancer cells 
from oxidative stress-induced suicide and thereby 
accelerate cancer progression.
It is now apparent that the balance between 
oxidants and antioxidants is very complex, and 
includes the role of ROS in a set of signalling pathways 
(33, 38, 39). For instance, ROS mediate apoptosis 
and affect NFkB, AP-1 and other transcription factors. 
Many other signal transduction pathways have shown 
sensitivity to ROS. Allen and Tresini (38) point out 
that the consequences of oxidant generation in cells 
are not limited to harmful effects, and Martin and 
Barrett (39) refer to ROS as "double-edged swords" 
in cellular processes, pointing out that low-dose 
effects can differ from high-dose effects. While the 
impact of ROS on physiologically relevant pathways 
in phagocytes is well known and crucial; low-dose 
effects of ROS on the cellular homeostasis are much 
less clear. It is therefore important to understand the 
impact of ROS on the cellular functions in order to 
elucidate potential harmful effects if the balance is 
counteracted by antioxidants.
Hyperbaric oxygen and hyperoxia are the known 
factors of DNA damage in vivo and in vitro (34). 
On the other hand, hyperbaric oxygen therapy in 
humans seems to be mutagenic and clastogenic 
in vitro, but not in vivo. Repeated exposure to 
hyperbaric oxygen leads to an adaptive response, 
apparently in terms of increased DNA repair activity, 
compensating for the mutagenicity of oxidative DNA 
lesions. Moreover, it must be taken into account that 
genetic polymorphisms exist at the levels of xenobiotic 
metabolising enzymes, enzymes maintaining a redox 
balance in cells and enzymes involved in DNA repair 
(40, 41).
Endogenous oxidative DNA damage
Reactive oxygen species are formed in all aerobic 
organisms as unavoidable by-products of cellular 
oxygen metabolism. Endogenous sources of ROS 
produce significant DNA damage either through 
direct interaction with DNA or through reactive 
Figure 2  Aspects of non-linear dose-response relationships between 
low and high levels of reactive oxygen species (ROS)
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intermediates from lipid peroxidation that couple 
to DNA bases. Endogenous ROS cause detectable 
background levels of DNA damage, namely in the 
form of oxidised bases (e.g. 8-oxoGua), apurinic (AP) 
sites, and strand breaks. Oxygen radicals also attack 
other cellular components such as lipids to generate 
reactive intermediates that couple to DNA and give 
rise to exocyclic etheno- and propane adducts (42, 
43). Specifically, etheno-bridged exocyclic DNA 
adducts, namely 1,N6-ethenodeoxyguanosine and 
3,N4-ethenodeoxycytidine, have been demonstrated at 
low and variable background levels in hepatic DNA of 
untreated rodents and in humans (44). Since reactive 
oxygen species are generally genotoxic, the question 
also arises whether chemicals that increase ROS 
production will add to an endogenously produced 
background level of DNA lesions or whether there 
are mechanisms which may produce non-linear dose-
effect relationships.
Endogenous DNA lesions are genotoxic and 
mutagenic, and affect oncogenes and tumor 
suppressor genes. Thus, it is likely that oxidative DNA 
damage by endogenous sources is an important factor 
in the aetiology of human cancer.
DNA repair
DNA repair is a crucial factor in maintaining a 
low and steady level of DNA damage. The level of 
chromosome breaks in lymphocytes indicates an 
association between poor repair and cancer risk 
(45). DNA repair is implicated in processes that 
promote human cancer, and deeper insights into 
these processes are important for advancing cancer 
aetiology, prevention and therapy (41). A reduced DNA 
repair activity for the oxidative lesion of 8-oxoguanine 
DNA N-glycosylase was reported in lung cancer 
patients (46). This particular DNA repair activity was 
not different between smokers and non-smokers, 
but other factors from nutrients to life style and 
occupational exposure might well be involved.
A surprisingly low increase in oxidative DNA base 
modifications in repair-deficient knockout mice was 
associated with a substantial increase in mutation 
frequency in the liver. However, these effects were 
too small to increase spontaneous cancer incidence 
in knockout animals (47). This limited effect seems 
to be due to a back-up repair system for oxidative 
DNA damage. Although oxidative DNA lesions are 
an important event in the initiation of cancer cells, 
data also show that this alone may not be sufficient 
to cause cancer (36). 
Other endogenous DNA adducts
The existence of "endogenous" DNA adducts has 
generally been accepted (48). The discussion first 
focused on so-called "I-compounds" ("indigenous 
compounds"), which are detected by the method of 
"32P-postlabelling" of DNA adducts (49). Physiological 
background levels differ between tissues and depend 
on sex, age and nutrition. Typically, one adduct per 
one million DNA bases is reported (48). These adducts 
will be associated with mutational consequences upon 
cell replication (50). In addition to their endogenous 
origin, these DNA adducts are typical products of the 
hepatic chemical carcinogens vinyl chloride and vinyl 
carbamate (44, 51, 52). Thus, a specific background 
of promutagenic DNA lesions is thought to arise 
from endogenous lipid peroxidation products (44). 
These DNA lesions are genotoxic, and they induce 
mutations that are common in mutated oncogenes 
and tumour suppressor genes. There is an argument 
that endogenous oxidative DNA damage could be an 
important factor in the aetiology of human cancers 
(36, 53).
Isoprene is a chemically defined endogenous 
carcinogen which, in physiologically activated form, 
serves to generate isoprenoids such as cholesterol, 
steroids, bile acids, and the side chain of K vitamins 
(54). Isoprene is metabolised into a di-epoxide (2-
methyl-2,2’-bi-oxirane) with mutagenic and genotoxic 
properties. In long-term bioassays on mice, isoprene 
was clearly carcinogenic, with a potency of about 1/10 
of 1,3-butadiene (55). The quantitative role of another 
chemically defined endogenous carcinogen, ethylene 
oxide, has been investigated more thoroughly (56, 57). 
Ethylene oxide is derived from endogenous ethylene 
and is therefore a natural metabolite (52, 58). Possible 
regulatory implications of the presence of this specific 
endogenous carcinogen for the regulation of its 
presence in consumer products have been discussed 
in literature (58, 59).
TYPES OF THRESHOLDS
The proposition to differentiate between types 
of thresholds is based on the idea that a chemical 
can not produce genotoxic effect at very low or 
immeasurable target concentrations (60). Basically, 
non-genotoxic carcinogens have been connected 
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with a "real" (61) or "perfect" (7) threshold. So-called 
"apparent" thresholds have been connected with rapid 
degradation (toxicokinetics) of the chemical or with 
other or additional factors that limit target exposure 
(61). Definitions were later proposed for "absolute", 
"real or biological", "apparent" and "statistical" 
thresholds (61). A "statistical" threshold is attributed 
to mitotic spindle poisons. Similarly, Hengstler et 
al. (7) distinguish between "perfect" and "practical" 
thresholds, depending on the type of mechanism 
(Figure 3). Streffer et al. (62) distinguish four basic 
types/groups of chemical carcinogens: 
• Non-threshold genotoxic carcinogens; the LNT 
model appears appropriate for the low-dose 
risk assessment. Regulations may be based 
on the ALARA principle ("as low as reasonably 
achievable"), technical feasibility, and other socio-
political considerations.
• Genotoxic carcinogens for which the existence 
of a threshold cannot be sufficiently supported; 
in these cases the LNT model is used as a 
default assumption based on the precautionary 
principle.
• Genotoxic carcinogens for which a "practical" 
threshold is supported by studies on mechanisms 
and/or toxicokinetics; health-based exposure 
limits may be based on an established NOAEL.
• Non-genotoxic carcinogens and non DNA-
reactive carcinogens; a "perfect" threshold for 
these compounds is associated with a NOAEL, and 
health-based exposure limits are to be derived.
Within this scheme, the distinctions between the 
groups B and C/D are of fundamental importance. 
These represent the most relevant areas of discussion 
and are also the major points of potential discrepancy 
in opinions. Key arguments referring to the chemicals 
acrylonitrile (group B), acrylamide (group B), 
formaldehyde (group C), vinyl acetate (group C) and 
trichloroethylene have been addressed in international 
discussions (7, 29). In the case of acrylamide, Dybing
and Sanner (13) recently seconded the use of linear 
risk extrapolation as default, and it was noted that this 
procedure was "highly conservative".
CONCLUSION
In general, it is now becoming evident that a 
diversity of methods of carcinogenic risk extrapolation 
to low doses must be applied, depending on the 
mode of action. There is a wide array of current 
scientific opinions ranging from the restriction of 
threshold models for non-genotoxic carcinogens 
(1) to biological thresholds for both DNA- and non-
DNA targeting chemicals (10, 63). The International 
Programme on Chemical Safety (IPCS) of the WHO 
has recently convened a Working Group on the 
"Harmonisation of Approaches to the Assessment of 
Risk from Exposure to Chemicals" to discuss a mode-
of-action framework that addresses the relevance of 
animal carcinogenesis for humans.
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Sažetak
NOVI ASPEKTI U KLASIFIKACIJI KANCEROGENA
U postojeæem sistemu klasifikacije kancerogenih tvari utvrðena je razlika izmeðu genotoksiènih i 
negenotoksiènih kemikalija. Za negenotoksiène kemikallije mogu se izvesti pretpostavljeni stupnjevi 
izlaganja kod kojih ne postoji znaèajan rizik od pojave raka kod ljudi. Za genotoksiène kancerogene moguæi 
su na primjer inducirani kromosomski efekti bez poèetka procesa mutageneze, dok genotoksièni toksini 
koji se ne vežu za DNA-molekulu, a djeluju na topoizomere ili diobeno vreteno ili su aneugeni, izazivaju 
kancerogene efekte jedino u visokim, toksiènim dozama. Za specifiène mehanizme klastrogenog djelovanja 
i procesa kancerogeneze koji se baziraju na reaktivnom kisiku postoji prag poèetka procesa. Kako su 
vrste kemikalija reaktivne na kisik (ROS) u naèelu genotoksiène, pojavljuju se pitanja da li kemikalije koje 
poveæavaju produkciju ROS-vrsta treba pridodati endogenim kancerogenima pozadinskog stupnja koji 
uzrokuju nelinearni odnos doze i uèinka. Uzimajuæi u obzir rasprave o prisutnosti endogenih kancerogena, 
sada postaje jasno da se kancerogeni rizik od niskih doza mora uzeti u obzir sukladno naèinu njihova 
djelovanja.
KLJUÈNE RIJEÈI: endogeni kancerogeni, genotoksiènost, graniène vrijednosti, kancerogeneza, 
kromosomski genotoksini, odnos doze i uèinka, reaktivni kisik
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